Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00768482
Other study ID # PRO-810
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date September 2008
Est. completion date December 2008

Study information

Verified date June 2017
Source Titan Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will measure the amount of buprenorphine found in the blood after taking sublingual buprenorphine tablets versus after implantation with 4 Probuphine (buprenorphine implants).


Description:

This is an open-label study intended to evaluate the relative bioavailability of 4 Probuphine implants versus 16mg QD sublingual buprenorphine, as determined by plasma BPN AUC(0-24), during 24 hours at steady state. This study will also provide open-label safety and tolerability data in patients treated with Probuphine.


Recruitment information / eligibility

Status Terminated
Enrollment 9
Est. completion date December 2008
Est. primary completion date December 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Voluntarily provide written informed consent prior to the conduct of any study related procedures

- Male or female, 18-75 years of age

- Meet the DSM-IV criteria for current opioid dependence

- Females of childbearing potential and fertile males must use a reliable means of contraception

Exclusion Criteria:

- Current diagnosis of Acquired Immune Deficiency Syndrome (AIDS)

- Received treatment for opioid dependence (e.g., methadone, BPN) within the previous 90 days

- Current diagnosis of chronic pain requiring opioids for treatment

- Candidates for only short term opioid treatment or opioid detoxification therapy

- Pregnant or lactating females

- Previous hypersensitivity or allergy to BPN or EVA-containing substances or naloxone

- Current use of agents metabolized through Cytochrome P450 3A4 (CYP 3A4) such as azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., erythromycin), and protease inhibitors (e.g., ritonavir, indinavir, and saquinavir)

- Current history of coagulopathy, and/or anti-coagulant therapy (such as warfarin)

- Meet the DSM-IV criteria for current dependence on any other psychoactive substances other than opioids or nicotine (e.g., alcohol, sedatives)

- Current use of benzodiazepines other than physician prescribed use

- Significant medical or psychiatric symptoms, cognitive impairment, or other factors which in the opinion of the Investigators would preclude compliance with the protocol, patient safety, adequate cooperation in the study, or obtaining informed consent

- Concurrent medical conditions (such as severe respiratory insufficiency) that may prevent the patient from safely participating in study; and/or any pending legal action that could prohibit participation and/or compliance in study

- Participated in a clinical study within the previous 8 weeks

- Previous participation in a Probuphine clinical trial

- Presence of aspartate aminotransferase (AST) levels greater than or equal to 3 X upper limit of normal and/or alanine aminotransferase (ALT) levels greater than or equal to 3 X upper limit of normal and/or total bilirubin greater than or equal to 1.5 X upper limit of normal and/or creatinine greater than or equal to 1.5 X upper limit of normal

- Clinically significant low platelet count with current history of coagulopathy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Probuphine (buprenorphine implant)
Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants)
Sublingual Buprenorphine
16 mg/day, QD

Locations

Country Name City State
United States Segal Institute For Clinical Research Fort Lauderdale Florida

Sponsors (1)

Lead Sponsor Collaborator
Titan Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Plasma BPN AUC(0-24)during 24 hours at steady state. Day -1, Day -2 and Week 4
Secondary Plasma BPN and NorBPN Cmax week 4
Secondary Time to maximum plasma BPN and NorBPN concentration (tmax) Day -2, Day -1 and Day 1
Secondary Plasma BPN and NorBPN AUC(0-24) during 24 hours at steady state week 4
Secondary Change in plasma BPN concentration 24 weeks
Secondary Number of subjects with adverse events as a measure of safety and tolerability Adverse events that occurred after the signing of informed consent until 14 days after study drug treatment has been discontinued, or AEs designated as possibly-related to study drug and Serious AEs until resolution or stabilization, were followed. approx. 11 weeks (due to study termination)
See also
  Status Clinical Trial Phase
Recruiting NCT03675386 - Reducing Opioid Use for Chronic Pain Patients Following Surgery N/A
Completed NCT02593474 - Medication-Assisted Treatment for Youth With Substance Use Disorders Phase 1
Completed NCT02294253 - Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone Phase 2/Phase 3
Completed NCT02282306 - Phone Interview to Prevent Recurring Opioid Overdoses N/A
Completed NCT01592461 - Starting Treatment With Agonist Replacement Therapies Follow-up Study N/A
Completed NCT01741350 - Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users N/A
Terminated NCT04121546 - Collaborative Care for Opioid Dependence And Pain Pilot Study N/A
Withdrawn NCT03368794 - Naloxone to TReatment Entry in the Emergency Setting N/A
Completed NCT03447743 - Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder Early Phase 1
Completed NCT04464421 - SMART Effectiveness Trial N/A
Recruiting NCT04189523 - Does Early Administration of Ultrasound Guided Regional Anesthesia for Long Bone Fractures Effect Long Term Patient Opioid Usage N/A
Completed NCT03305666 - Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Phase 4
Recruiting NCT04003948 - Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification Phase 2
Not yet recruiting NCT03813095 - Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction Phase 2
Terminated NCT02935101 - Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants Phase 2
Completed NCT01895270 - Improving Buprenorphine Detoxification Outcomes With Isradipine Phase 1/Phase 2
Completed NCT01717963 - Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway Phase 3
Completed NCT01425060 - Improving Effective Contraceptive Use Among Opioid-maintained Women Phase 1
Completed NCT02324725 - Biomarkers of Injectable Extended Release Naltrexone Treatment Phase 4
Completed NCT01188421 - Medications Development for Drug Abuse Disorders Phase 1/Phase 2

External Links